

VERTEX PHARMACEUTICALS INC / MA  
Form 8-K  
February 10, 2004

[QuickLinks](#) -- Click here to rapidly navigate through this document

---

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **February 10, 2004**

---

## VERTEX PHARMACEUTICALS INCORPORATED

(Exact name of registrant as specified in its charter)

**MASSACHUSETTS**

(State or other jurisdiction of incorporation)

**000-19319**

(Commission File Number)

**04-3039129**

(IRS Employer Identification No.)

**130 Waverly Street**

**Cambridge, Massachusetts 02139**

(Address of principal executive offices) (Zip Code)

**(617) 444-6100**

(Registrant's telephone number, including area code)

---

#### ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

(c)

Exhibits

99.1 Press Release of Vertex Pharmaceuticals Incorporated dated February 10, 2004.

99.2 Excerpt from Offering Memorandum.

#### ITEM 9. REGULATION FD.

The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly

## Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 8-K

set forth by specific reference in such filing.

On February 10, 2004, Vertex Pharmaceuticals Incorporated (the "Registrant") issued a press release announcing that certain holders of its existing 5% Convertible Subordinated Notes due 2007 have agreed to exchange approximately \$153.5 million in aggregate principal amount of such existing Notes for approximately \$153.5 million in aggregate principal amount of newly issued 5<sup>3</sup>/<sub>4</sub>% Convertible Subordinated Notes due 2011. The press release is attached hereto as Exhibit 99.1 and hereby incorporated by reference in its entirety.

In connection with the exchange transaction described above, the Registrant disclosed certain unaudited pro forma condensed consolidated financial information in an Offering Memorandum (the "Excerpt"). The Excerpt has been furnished as Exhibit 99.2 hereto and hereby incorporated by reference in its entirety.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VERTEX PHARMACEUTICALS INCORPORATED  
(Registrant)

/s/ IAN F. SMITH

---

Ian F. Smith  
Senior Vice President and Chief Financial Officer

Date: February 10, 2004

### EXHIBIT INDEX

The following exhibits are furnished as part of this current report on Form 8-K:

Exhibit No.	Description
99.1	Press Release of Vertex Pharmaceuticals Incorporated dated February 10, 2004
99.2	Excerpt from Offering Memorandum

### QuickLinks

[ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.](#)

[ITEM 9. REGULATION FD.](#)

[SIGNATURES](#)

[EXHIBIT INDEX](#)